

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 June 2025 (26.06.2025)



(10) International Publication Number
WO 2025/137441 A1

(51) International Patent Classification:

A61K 51/08 (2006.01) A61K 103/30 (2006.01)
A61P 35/00 (2006.01) A61K 103/40 (2006.01)
C07K 14/655 (2006.01)

(21) International Application Number:

PCT/US2024/061269

(22) International Filing Date:

20 December 2024 (20.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/614,474 22 December 2023 (22.12.2023) US

(71) Applicant: RAYZEBIO, INC. [US/US]; 5505 Morehouse Dr., Suite 300, San Diego, California 92121 (US).

(72) Inventors: BHAT, Abhijit; c/o RayzeBio, Inc., 5505 Morehouse Dr., Suite 300, San Diego, California 92121 (US). SMITH, Nicholas D.; c/o RayzeBio, Inc., 5505 Morehouse Dr., Suite 300, San Diego, California 92121 (US). BAKAS, Nicole; c/o RayzeBio, Inc., 5505 Morehouse Dr., Suite 300, San Diego, California 92121 (US). NONCOVICH, Alain; c/o RayzeBio, Inc., 5505 Morehouse Dr., Suite 300, San Diego, California 92121 (US). HUDSON, Andrew R.; c/o RayzeBio, Inc., 5505 Morehouse Dr., Suite 300, San Diego, California 92121 (US). TRAN, Joe Anh; c/o RayzeBio, Inc., 5505 Morehouse Dr., Suite 300, San Diego, California 92121 (US). NAPIER, Patrick; c/o RayzeBio, Inc., 5505 Morehouse Dr., Suite 300, San Diego, California 92121 (US). BRAVO, Yalda; c/o RayzeBio, Inc., 5505 Morehouse Dr., Suite 300, San Diego, California 92121 (US).

(74) Agent: SCARR, Rebecca B. et al.; McNeill PLLC, 245 First Street, 18th Floor, Cambridge, Massachusetts 02142 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: RADIOPHARMACEUTICALS TARGETING SOMATOSTATIN RECEPTOR 2 AND USES THEREOF

(57) Abstract: Provided herein are peptides and conjugates (e.g., radiopharmaceutical conjugates) having avidity for a somatostatin receptor and uses thereof. The conjugate can comprise a 6-mer peptide, such as a monocyclic 6-mer peptide, a metal chelator, and optionally a linker connecting the peptide to the chelator. The radiopharmaceutical conjugate can further comprise a radionuclide bound to the metal chelator. Further provided herein are methods of preparing the conjugates, and methods of treating cancer by administering the described conjugates to a subject in need thereof.

WO 2025/137441 A1